- Home
- ABTS vs KZIA Comparison
ABTS vs KZIA Comparison
Compare ABTS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | KZIA |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 186.7M |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | ABTS | KZIA |
|---|---|---|
| Price | $1.31 | $10.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 49.8K | ★ 317.2K |
| Earning Date | 04-29-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $4.86 |
| 52 Week High | $10.86 | $17.40 |
Technical Indicators
Market Signals| Indicator | ABTS | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 39.10 |
| Support Level | $1.02 | $5.15 |
| Resistance Level | $1.56 | $14.85 |
| Average True Range (ATR) | 0.12 | 0.88 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 46.69 | 11.71 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.